Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb;11(1):423-434.
doi: 10.1007/s40121-021-00568-7. Epub 2021 Dec 14.

Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials

Pedro L Gonzalez #  1   2 , Urania Rappo #  3   4 , Karthik Akinapelli  5   6 , Jennifer S McGregor  5 , Sailaja Puttagunta  7   4 , Michael W Dunne  7   6
Affiliations

Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials

Pedro L Gonzalez et al. Infect Dis Ther. 2022 Feb.

Abstract

Introduction: Dalbavancin is a long-acting, bactericidal, lipoglycopeptide antibiotic approved by the US Food and Drug Administration and the European Medicines Agency for treatment of acute bacterial skin and skin structure infections in adults, with potent activity against Gram-positive pathogens, including methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Here we describe the clearance and clinical outcomes of patients with S. aureus bacteremia in five clinical trials of skin and skin structure infections or catheter-related bloodstream infections that evaluated the efficacy and safety of dalbavancin.

Methods: Patients with uncomplicated S. aureus bacteremia identified in blood cultures drawn at baseline (before study drug) with at least one follow-up blood culture are described from four phase 3 trials in skin and skin structure infections and one phase 2 catheter-related infection study. Dalbavancin was administered as a single-dose (1500 mg intravenous [IV]) or a two-dose regimen (1000 mg IV on day 1, 500 mg IV on day 8). Comparators included vancomycin IV or linezolid IV/oral for 10-14 days.

Results: All 39 patients (100%) who received dalbavancin, including 8 patients on the single-dose regimen, had clearance of bacteremia versus 19/20 patients (95%) treated with comparators (vancomycin or linezolid). At end of treatment, 33/36 dalbavancin-treated patients (92%) achieved clinical success versus 18/23 patients (78%) treated with comparators.

Conclusions: All 39 patients with uncomplicated S. aureus bacteremia treated with dalbavancin (single- or two-dose regimen) and with follow-up blood cultures had clearance of their bloodstream infection. Clinical response rates were similar to daily comparator therapy for 10-14 days.

Trial registration: DISCOVER 1, NCT01339091; DISCOVER 2, NCT01431339; DUR001-303, NCT02127970; VER001-9; VER001-4, NCT00057369.

Keywords: Acute bacterial skin and skin structures infections; Bacteremia; Dalbavancin; Gram-positive.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Serum concentration of dalbavancin 1500 mg after intravenous administration as a 30-min infusion in a single-dose or two-dose regimen. Adapted with permission from Dunne M and Puttagunta S. Clearance of Staphylococcus aureus bacteremia in patients treated with dalbavancin. Presented at IDWeek, October 2–6, 2013; San Francisco, CA. http://www.idweek.org
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Economou NJ, Nahoum V, Weeks SD, et al. A carrier protein strategy yields the structure of dalbavancin. J Am Chem Soc. 2012;134:4637–4645. doi: 10.1021/ja208755j. - DOI - PMC - PubMed
    1. Dalvance® (dalbavancin). Full Prescribing Information. Parsippany: Durata Therapeutics US Ltd.; 2021.
    1. Xydalba (dalbavancin). Summary of product characteristics. Amsterdam: Durata Therapeutics International BV; 2017.
    1. Dunne MW, Puttagunta S, Giordano P, et al. A randomized clinical trial of single-dose versus weekly dalbavancin for treatment of acute bacterial skin and skin structure infection. Clin Infect Dis. 2016;62:545–551. doi: 10.1093/cid/civ982. - DOI - PMC - PubMed
    1. Boucher HW, Wilcox M, Talbot GH, et al. Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med. 2014;370:2169–2179. doi: 10.1056/NEJMoa1310480. - DOI - PubMed

Associated data

LinkOut - more resources